Search

for
Search:

Sort by

Research

30 / 337 results

Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The Allegro Phase 2b/3 Randomized Clinical Trial

research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial

4 citations , October 2024 in “American Journal of Clinical Dermatology”

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

November 2024 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

research Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

6 citations , March 2024 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata

February 2026 in “The Journal of Dermatology”

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

research Ritlecitinib (Litfulo)

August 2026 in “Canadian Journal of Health Technologies”

Litfulo is recommended for treating severe alopecia areata in people 12 and older, as it helps hair regrowth.

research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review

January 2026

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: Three-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies

research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies

March 2026 in “American Journal of Clinical Dermatology”

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

research Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial

3 citations , February 2025 in “Journal of Dermatological Treatment”

Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.

research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial

4 citations , March 2025 in “The Journal of Dermatology”

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial

7 citations , October 2024 in “Journal of the American Academy of Dermatology”

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies

3 citations , November 2023 in “Journal of Investigative Dermatology”

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

September 2023 in “Dermatology and therapy”

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3

1 citations , October 2025 in “International Journal of Dermatology”

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

The FDA Approves Litfulo® (Ritlecitinib) for the Treatment of Severe Alopecia Areata in Adolescents and Adults

research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos

September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)”

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

research Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses

1 citations , June 2026 in “Dermato”

Ritlecitinib, a JAK3 and TEC kinase inhibitor, shows promise as an effective treatment for alopecia areata (AA), demonstrating significant hair regrowth and reduced disease severity in both clinical trials and real-world studies. The ALLEGRO phase 2b/3 trial with 522 patients highlighted its efficacy, although prior treatments like corticosteroids influenced early responses. Real-world evidence from Italy and China supports its effectiveness, especially in JAK inhibitor-naïve patients, with mild adverse events reported. Studies in adolescents and children also showed significant improvements. However, the literature is limited and heterogeneous, necessitating larger, long-term studies to confirm its long-term safety and effectiveness, particularly in diverse and pediatric populations.

research Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary

May 2025 in “Immunotherapy”

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

October 2025 in “Dermatology and Therapy”

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months in Patients with Alopecia Areata from the Allegro Clinical Trial Program

research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program

July 2025 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Prediction of Long-Term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the Allegro Clinical Trial Program

research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program

March 2025 in “SKIN The Journal of Cutaneous Medicine”

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata

23 citations , October 2024 in “British Journal of Dermatology”

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study

1 citations , September 2023 in “Journal of the American Academy of Dermatology”

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

research Ritlecitinib in severe alopecia areata: a profile of its use

September 2024 in “Drugs & Therapy Perspectives”

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss

4 citations , July 2023 in “Nature Medicine”

The FDA approved a new Pfizer drug for hair loss in teens.

research Alopecia areata and ritlecitinib: Unravelling response trajectories

May 2025 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

research Janus kinase inhibitors for alopecia areata

7 citations , August 2023 in “Journal of the American Academy of Dermatology”

JAK inhibitors offer new hope for treating severe alopecia areata.

research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study

1 citations , July 2025 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.